Pages that link to "Q43134067"
Jump to navigation
Jump to search
The following pages link to Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study (Q43134067):
Displaying 28 items.
- Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) (Q26770391) (← links)
- Beyond hypomethylating agents failure in patients with myelodysplastic syndromes (Q26827079) (← links)
- TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation (Q27853319) (← links)
- Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends (Q30235355) (← links)
- Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial (Q33428549) (← links)
- Current therapy of myelodysplastic syndromes (Q34013796) (← links)
- Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia (Q34350209) (← links)
- Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes (Q34783754) (← links)
- Expanding role of lenalidomide in hematologic malignancies (Q35592305) (← links)
- Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation (Q36810315) (← links)
- Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study (Q37074311) (← links)
- The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm (Q38160051) (← links)
- Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome (Q38172875) (← links)
- Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide (Q38195796) (← links)
- The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes (Q38570399) (← links)
- Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications (Q38758162) (← links)
- Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings (Q38961023) (← links)
- A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia (Q39240258) (← links)
- Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group (Q40555529) (← links)
- Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial. (Q41080080) (← links)
- Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities (Q41764055) (← links)
- Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality? (Q42573901) (← links)
- Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia (Q42923384) (← links)
- Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring (Q42935881) (← links)
- Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report (Q51111341) (← links)
- Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. (Q52604951) (← links)
- Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML. (Q55515597) (← links)
- Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts (Q94503173) (← links)